What insurance policy changes affect CPT 36465?

There are 7 tracked policy changes affecting CPT 36465, including updates from Aetna, Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 36465?

Payers that have issued tracked updates for CPT 36465 include: Aetna, Independence Blue Cross.

How do I get notified when CPT 36465 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 36465. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 36465?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

36465 — A doctor injects a sclerosing solution into a single vein to close it off.: Insurance Policy Changes

36465 Insurance Policy Changes

CPT 36465, in plain terms, covers A doctor injects a sclerosing solution into a single vein to close it off. CPT 36465 is referenced in 7 tracked payer policy changes from Aetna and Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 36465 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Prolotherapy and Sclerotherapy (CPB 0207, reviewed 2026-03-27)

Aetna·Effective Mar 27, 2026

Aetna has updated its prolotherapy and sclerotherapy policy (CPB 0207, effective 2026-03-27) to clarify that prolotherapy is considered experimental/investigational for ALL indications including common musculoskeletal conditions (back pain, knee osteoarthritis, tendinopathy, plantar fasciitis, etc.). Sclerotherapy remains covered only for specific clinical indications (varices, hemorrhoids, cysts, malformations). Billing teams must ensure claims for prolotherapy procedures are not submitted as covered services and must verify sclerotherapy indications meet strict medical necessity criteria before processing.

36465 Insurance Policy Changes

Prolotherapy and Sclerotherapy (CPB 0207, reviewed 2026-03-27)

MA11.001l, Treatment of Varicose Veins of the Lower Extremities and Perforator Vein Incompetence

MA11.001l, Treatment of Varicose Veins of the Lower Extremities and Perforator Vein Incompetence

MA11.001k, Treatment of Varicose Veins of the Lower Extremities and Perforator Vein Incompetence

11.02.01v, Treatment of Varicose Veins of the Lower Extremities and Perforator Vein Incompetence

11.02.01v, Treatment of Varicose Veins of the Lower Extremities and Perforator Vein Incompetence

11.02.01u, Treatment of Varicose Veins of the Lower Extremities and Perforator Vein Incompetence